Edward Greeno, M.D.
Upcoming SlideShare
Loading in...5
×
 

Like this? Share it with your network

Share

Edward Greeno, M.D.

on

  • 384 views

Creating Survivors: A century of treatment advances in colorectal cancer

Creating Survivors: A century of treatment advances in colorectal cancer

Statistics

Views

Total Views
384
Views on SlideShare
383
Embed Views
1

Actions

Likes
0
Downloads
1
Comments
0

1 Embed 1

http://localhost 1

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Edward Greeno, M.D. Presentation Transcript

  • 1. Creating Survivors:A Century of Treatment Advances inColorectal Cancer Edward Greeno, MD Associate Professor of Medicine, University of Minnesota Medical Director, Masonic Cancer Clinic Executive Medical Director, UMPhysicians Cancer Care
  • 2. 1900’s to 1960’s Surgery 2
  • 3. 1965 to 1995 One Chemotherapy drug: 5-Fluorouracil Screening 3
  • 4. Outcomes with 5-FU 30 years of progress Survival 6-12 months  Probable 1-2 mo improvement in survival (Fancy 5FU) (5FU) Ed finished fellowship Ed started kindergardenFrom:Lancet7/29/00
  • 5. Screening Fecal Occult Blood testing randomized trials  MN: 48,000 annual 10%+ tests 33% lower CRC mortality  UK: 150,00 biennial 2%+ tests 15% lower CRC mortality  DN: 62,000 biennial 1%+ 18% lower CRC mortality 5
  • 6. 1995 to Present Prevention Adjuvant Therapy Multiple new chemotherapies Personalized Medicine 6
  • 7. Prevention Diet  Populations with low fat, high fiber diets rich in fruits and vegetables = lower risk  Patients after resection of colon cancer who follow good diet => lower risk of recurrence Exercise  Patientsafter resection of colon cancer who exercise regularly => lower risk of recurrence 7
  • 8. Prevention in high riskpopulations Identification of high risk patients  Geneticscreening  Inflammatory bowel disease  Frequent polyps Regular colonscopy with resection of polyps => 50% risk reduction Resection of the colon => 90% reduction 8
  • 9. Adjuvant Therapy Definition:Treatment added to primary curative therapy to improve cure rates Frequent recurrences after surgery  10-80% depending on stage Due to occult (tiny & not visible) spread 9
  • 10. Adjuvant Therapy Chemotherapy can cure microscopic metastatic disease Studies in early 90’s show 20-30% risk reduction with 5FU Additionof Oxaliplatin improved reduction to 40-50% 10
  • 11. NeoAdjuvant Therapy Using regimens prior to surgery Dramatic response rates allow curative- intent resection of previously inoperable patients. 11
  • 12. New Drugs Oral agents allow easier adminstration New cytoxic agents improve control of metastatic disease Better understanding of cancer biology allows better identification of targets 12
  • 13. Oral 5-FU 5-FU poor, highly variable bioavalibility  To work best needs long IV infusion UFT:  5FU congener plus Uracil  comparable to IV 5FU Ralitrexed  Probably less effective than IV 5FU Capecitabine (Xeloda) 13
  • 14. Capecitabine vs Bolus IV 5FU  Van Cutsem et al, JCO 2001
  • 15. Irinotecan vs Best Supportive Care 100% Irinotecan Best Supportive Care Survival After 50% failing 5FU 0% 6.5mo 11.5mo 18moCunningham, Lancet 1998
  • 16. Oxaliplatin  Survival with Frontline Oxaliplatin/5FU 100% Oxaliplatin plus 5FU 5FU alone 50%From: 0%JCO 6 12 18 24 30 36 mo8/15/00
  • 17. Cytotoxic chemotherapy ofColorectal Cancer: SummaryPercentSurvival 0 Drugs (but well enough for a study) 1 Drug 2 Drugs 50% 3 Drugs Time (mo) 12 14 16 18
  • 18. New targeted agents Angiogenesis inhibitors EGFR Inhibitors
  • 19. Angiogenesis Inhibitors The concept: A tumor must grow a blood supplyBerger, Nature Reviews 2003
  • 20. VEGF Inhibition in Colon Ca
  • 21. 4 months better The results Median SurvivalHurwitz, NEJM 2004
  • 22. Epidermal Growth Factor Receptor Subfamily of growth receptors  EGFR, HER2/neu, HER3, HER4 Activation leads to:  Ras/MAPK/Cyclin-D1 activation  Cellproliferation  Angiogenesis, Inhibition of apoptosis, metastases Autocrine growth pathway frequently activated in human tumors
  • 23. Epidermal Growth Factor ReceptorInhibition Ciardiello, Clin Can Res, 2001
  • 24. Cetuximab-current dataSurvival benefit vs. BSC  After failure of conventional therapy  QOL of life also better NCI CTG CO.17 1.0 Jonker et al, NEJM 2007 0.8Overall CETUXIMABsurvival 0.6 BEST SUPPORTIVE CARE P=0.0046 0.4 0.2 0 6 12 18 24 Months
  • 25. Epidermal Growth Factor ReceptorInhibition Ciardiello, Clin Can Res, 2001
  • 26. Regorafenib Randomized study in colon cancer patients failing all other therapies  Survival improved 2 months 26 www.thelancet.com Vol 381 January 26, 2013
  • 27. Aflibercept Complex molecule to block multiple pathways--1 month survival benefit 27 J Clin Oncol 30:3499-3506.
  • 28. Drug Therapy of AdvancedColorectal Cancer:Impact of new agentsPercent 0 Drugs 4 DrugsSurvival 1 Drug 5 Drugs 2 Drugs 6 Drugs 3 Drugs 7 Drugs 50% Time (mo) 12 14 16 18 >30 months median
  • 29. Personalized Medicine New tools create much more detailed information about individual patient tumors Allow more precise selection of therapy Most of the promise just beginning to be realized 29
  • 30. Selecting patients for adjuvanttherapy Microsatellite instability (MSI)  Genetic alteration in some tumors  Predicts lower recurrence risk  Predicts less effect of chemotherapy Avoid chemotherapy in low risk patients with MSI Molecular predictors being developed for multiple cancers 30
  • 31. Cetuximab-importance of KRASIf KRAS is mutated:Cetuximab never works  NCI CTG CO.17  Karepetis et al, NEJM 2008 31
  • 32. New Therapies for Colon Cancer For 60 years all we had was surgery Inthe next 30 we learned to do screening and developed one chemotherapy drug Inthe past 15 we dramatically improved outcomes The next 5 years will eclipse all of that 32
  • 33. Advances In the Pipeline Genetically Engineered Salmonella  Infects tumor cells  Induces immune destruction Minnelide—Plant derived drug  downregulates protective mechanisms in cancer cells Genetically engineered Adenovirus  Infect and destroy tumor cells 33
  • 34. Salmonella-pIL2Colorectal livermetastases reduced inmice orally administeredSalmonella-IL2 vs.saline (control) orSalmonella-no-IL2.Developed By DanSaltzmanFirst in human Phase Istudy nearly completewith no significant ttoxicity
  • 35. Minnelide vs. Pancreas Cancer Science Translational Medicine, 17 October 2012 Vol 4 Issue 156  Effective in mice even with Developed by Ashok fresh patient xenograft rather Saluja than cell line  Effective even when tumor First in human trial allowed to grow to massive to begin in June volume
  • 36. AdenovirusDeveloped by Masato Yamamoto ControlsEffective inmouse xenograftmodel Modified virus First in human trial awaiting toxicity studies and funding